TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Dimerix Limited ( (AU:DXB) ) is now available.
Dimerix Limited announced the successful completion of the seventh Independent Data Monitoring Committee (IDMC) review of its ACTION3 Phase 3 FSGS kidney trial, with no safety concerns raised. This endorsement supports the strong safety profile of DMX-200, positioning it as a promising treatment option in the FSGS landscape, offering hope to patients with limited options and representing a significant commercial opportunity in an underserved market.
The most recent analyst rating on (AU:DXB) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
More about Dimerix Limited
Dimerix Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for inflammatory diseases, including kidney and respiratory diseases. The company is advancing its proprietary Phase 3 product candidate DMX-200 for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and DMX-700 for respiratory disease. Dimerix utilizes its Receptor Heteromer Investigation Technology (Receptor-HIT) platform to identify new drug opportunities.
Average Trading Volume: 1,198,023
Technical Sentiment Signal: Buy
Current Market Cap: A$288.2M
For detailed information about DXB stock, go to TipRanks’ Stock Analysis page.